Proteome-informed machine learning studies of cocaine addiction
  Cocaine addiction accounts for a large portion of substance use disorders and
threatens millions of lives worldwide. There is an urgent need to come up with
efficient anti-cocaine addiction drugs. Unfortunately, no medications have been
approved by the Food and Drug Administration (FDA), despite the extensive
effort in the past few decades. The main challenge is the intricate molecular
mechanisms of cocaine addiction, involving synergistic interactions among
proteins upstream and downstream of dopamine transporter (DAT) functions
impacted by cocaine. However, traditional in vivo or in vitro experiments can
not address the roles of so many proteins, highlighting the need for innovative
strategies in the field. We propose a proteome-informed machine learning/deep
learning (ML/DL) platform to discover nearly optimal anti-cocaine addiction
lead compounds. We construct and analyze proteomic protein-protein interaction
(PPI) networks for cocaine dependence to identify 141 involved drug targets and
represent over 60,000 associated drug candidates or experimental drugs in the
latent space using an autoencoder (EA) model trained from over 104 million
molecules. We build 32 ML models for cross-target analysis of these drug
candidates for side effects and repurposing potential. We further screen the
absorption, distribution, metabolism, excretion, and toxicity (ADMET)
properties of these candidates. Our platform reveals that essentially all of
the existing drug candidates, including dozens of experimental drugs, fail to
pass our cross-target and ADMET screenings. Nonetheless, we have identified two
nearly optimal leads for further optimization.
